RAPT Therapeutics is a clinical‑stage biopharmaceutical company that discovers, develops, and commercializes innovative immunology‑based therapies for patients with inflammatory and immunological disorders. Leveraging proprietary expertise in immune modulation, the company designs drugs that target the underlying immune pathways driving disease. Its pipeline focuses on conditions such as autoimmune diseases and other chronic inflammatory states. RAPT’s distinctive advantage lies in its deep scientific foundation and commitment to translating mechanistic insights into clinically relevant treatments.
The Clinical Trial Liaison will support the RTP904 Clinical Development program in the US, Canada, Australia, or other territories. The CTL will serve as a liaison between the RAPT Study Execution Team, clinical study sites, and research team personnel.
RAPT Therapeutics is a clinical‑stage biopharmaceutical company that discovers, develops, and commercializes innovative immunology‑based therapies for patients with inflammatory and immunological disorders. Leveraging proprietary expertise in immune modulation, the company designs drugs that target the underlying immune pathways driving disease. Its pipeline focuses on conditions such as autoimmune diseases and other chronic inflammatory states. RAPT’s distinctive advantage lies in its deep scientific foundation and commitment to translating mechanistic insights into clinically relevant treatments.